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Introduction {#sec005}
============

Urinary bladder cancer is one of the most frequently diagnosed neoplasms, with an estimated 429,800 new cases and 165,100 deaths occurred in 2012 worldwide \[[@pone.0174746.ref001]\]. Although patients initially with non-muscle-invasive (NMI) tumor generally display favorable prognosis, they, especially those with high-grade tumor, have a relatively high risk of tumor recurrence with progression to muscle invasion after transurethral resection even with currently available intravesical pharmacotherapy. On the other hand, those with muscle-invasive (MI) tumor often develop disease progression or metastasis despite undergoing more aggressive treatment modalities, such as radical cystectomy with or without neoadjuvant or adjuvant systemic chemotherapy. Therefore, identification of key molecules involving bladder cancer outgrowth is urgently required, which may successively provide novel tumor markers that predict the prognosis as well as novel targeted therapy in patients with bladder cancer.

Various epidemiological and clinical studies have demonstrated that men have a substantially higher risk of bladder cancer, while women tend to have more aggressive tumors \[[@pone.0174746.ref001]--[@pone.0174746.ref007]\]. These observations have prompted research on sex hormone receptors, such as androgen receptor (AR) and estrogen receptors (ERs), in bladder cancer \[[@pone.0174746.ref008]--[@pone.0174746.ref010]\]. Indeed, preclinical evidence has suggested a critical role of AR/ERs in the development and progression of urothelial cancer arising in the upper and lower urinary tracts. Specifically, androgens have been shown to promote bladder tumorigenesis, as well as bladder cancer cell proliferation, migration, and invasion, via the AR pathway \[[@pone.0174746.ref011]--[@pone.0174746.ref022]\]. Non-androgen-mediated AR activation in bladder cancer cells \[[@pone.0174746.ref023]\] and androgen-induced tumorigenesis via the non-AR pathway \[[@pone.0174746.ref014]\] have also been documented. Moreover, AR activation has been correlated with resistance to chemotherapy in bladder cancer cells \[[@pone.0174746.ref024], [@pone.0174746.ref025]\]. In contrast, estrogens likely exert both stimulatory and inhibitory actions on bladder cancer outgrowth, which may be cell-specific and/or dependent on the functional activity of ERα and ERβ \[[@pone.0174746.ref011], [@pone.0174746.ref012], [@pone.0174746.ref026]--[@pone.0174746.ref032]\].

Meanwhile, conflicting data as to the expression of sex hormone receptors in urothelial tumors of the lower urinary tract, and its associations with tumor grade/stage or patient outcomes have been reported \[[@pone.0174746.ref033]\]. Therefore, in the current study using a meta-analysis, we aimed to determine the expression status of AR, ERα, and ERβ immunohistochemically detected in different grades or stages of bladder cancers and its potential role as prognosticators.

Materials and methods {#sec006}
=====================

Search strategy {#sec007}
---------------

A systematic literature search and subsequent quantitative analysis were planned, conducted, and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@pone.0174746.ref034]\] ([S1 Fig](#pone.0174746.s001){ref-type="supplementary-material"}, [S1 Table](#pone.0174746.s004){ref-type="supplementary-material"}). We performed a computerized bibliographic search of the PubMed, Web of Science, and Cochrane library in February 2017 for publications after 2004 in order to find the articles demonstrating the results of immunohistochemistry (IHC) of sex hormone receptors (*i*.*e*. AR, ERα, and/or ERβ) in bladder cancer tissue specimens obtained by transurethral resection or cystectomy from patients who did not receive radiotherapy or systemic chemotherapy preoperatively. The search strategy included the following keywords combined: 1) "androgen receptor" and "bladder cancer"; 2) "androgen receptor" and "urothelial carcinoma"; 3) "estrogen receptor" and "bladder cancer"; and 4) "estrogen receptor" and "urothelial carcinoma". We selected only studies published in English in peer reviewed journals, while the results from letters and abstracts for meetings were excluded.

Selection criteria {#sec008}
------------------

Eligible studies in this meta-analysis included those showing pathological and/or prognostic information in bladder cancer patients stratified with the expression of AR, ERα, or ERβ determined by IHC. Specifically, these studies compared the positivity of these receptors between non-tumor/normal bladder and tumor, low and high grades, and/or NMI and MI, or assessed prognostic significance of their expression \[*e*.*g*. recurrence-free survival (RFS) or progression-free survival (PFS) in patients with NMI bladder cancer\]. In the case of multiple publications from the same institution potentially with identical or overlapping patient cohorts, the most informative or the most complete study was used for our analysis. There was no restriction on geographical location of the studies.

Data extraction {#sec009}
---------------

We recorded the following information about each eligible study: first author's name; journal; year of publication; and number of patients analyzed. We also recorded available data on positivity of sex hormone receptors in non-tumor versus tumor, male versus female, low versus high grades, low versus high stages, RFS, and PFS ([Table 1](#pone.0174746.t001){ref-type="table"}), as well as odds ratio (OR), hazard ratio (HR), and 95% confidence interval (CI). Data of multivariate analysis were included in the present study; if these data were not available, then univariate analysis data were used.

10.1371/journal.pone.0174746.t001

###### Eligible immunohistochemical studies assessing the expression of sex hormone receptors in bladder tumors.

![](pone.0174746.t001){#pone.0174746.t001g}

  Author, year \[reference\]                  Receptor   Patients (N)   Non-tumor (non-neoplastic urothelium) vs Tumor   Gender   Tumor grade                                 Tumor stage   Survival analysis (NMI)                                                                                                                                         
  ------------------------------------------- ---------- -------------- ------------------------------------------------ -------- ------------------------------------------- ------------- ------------------------- ------- ------ ------ ---------------------------------------------- ---------- ------ ---------------------------------------------- ---------
  Boorjian, 2004 \[[@pone.0174746.ref038]\]   AR         49             86%                                              53%      0.001                                       61%           31%                       0.104   89%    49%    0.055                                          75%        21%    0.002                                          NA
  Boorjian, 2009 \[[@pone.0174746.ref039]\]   AR         55             NA                                               44%      0.06[\*](#t001fn002){ref-type="table-fn"}   NA            NA                        NA      NA     NA     NA                                             59%        33%    0.095                                          NA
  Kauffman, 2011 \[[@pone.0174746.ref040]\]   AR         59             84%                                              51%      \<0.001                                     NA            NA                        NA      NA     NA     NA                                             NA         NA     NA                                             NA
  Mir, 2011 \[[@pone.0174746.ref041]\]        AR         472            NA                                               13%      NA                                          14%           8%                        0.159   12%    13%    1.000                                          9%         15%    0.086                                          NA
  Tuygun, 2011 \[[@pone.0174746.ref042]\]     AR         139            0%                                               51%      \<0.001                                     53%           41%                       0.356   64%    37%    0.002                                          60%        21%    \<0.001                                        RFS/PFS
  Miyamoto, 2012 \[[@pone.0174746.ref036]\]   AR         188            80%                                              42%      \<0.001                                     42%           43%                       1.000   55%    36%    0.023                                          51%        33%    0.018                                          RFS/PFS
  Jing, 2014 \[[@pone.0174746.ref020]\]       AR         58             NA                                               53%      NA                                          57%           43%                       0.540   55%    50%    0.781                                          49%        69%    0.225                                          NA
  Mashhadi, 2014 \[[@pone.0174746.ref043]\]   AR         120            0%                                               22%      \<0.001                                     NA            NA                        NA      NA     NA     \<0.001[\*](#t001fn002){ref-type="table-fn"}   NA         NA     \<0.001[\*](#t001fn002){ref-type="table-fn"}   NA
  Nam, 2014 \[[@pone.0174746.ref044]\]        AR         169            NA                                               37%      NA                                          38%           31%                       0.515   39%    33%    0.485                                          43% (Ta)   NA     0.048                                          RFS/PFS
                                                                                                                                                                                                                                                                                           30% (T1)          (Ta vs T1)                                     
  Miyamoto, 2012 \[[@pone.0174746.ref036]\]   ERα        188            50%                                              27%      \<0.001                                     28%           25%                       0.842   38%    23%    0.048                                          35%        19%    0.014                                          NS
  Mashhadi, 2014 \[[@pone.0174746.ref043]\]   ERα        120            2%                                               3%       0.671                                       NA            NA                        NA      NA     NA     NA                                             NA         NA     NA                                             NA
  Croft, 2005 \[[@pone.0174746.ref045]\]      ERβ        92             NA                                               22%      NA                                          NA            NA                        NA      12%    33%    0.021                                          NA         NA     NA                                             NA
  Shen, 2006 \[[@pone.0174746.ref046]\]       ERβ        224            NA                                               63%      NA                                          NA            NA                        NA      58%    70%    0.085                                          54%        80%    \<0.001                                        NA
  Kontos, 2010 \[[@pone.0174746.ref047]\]     ERβ        111            93%                                              76%      0.041                                       NA            NA                        NA      NA     NA     NA                                             NA         54%    NA                                             NA
  Tuygun, 2011 \[[@pone.0174746.ref042]\]     ERβ        139            7%                                               30%      \<0.001                                     33%           23%                       0.455   22%    31%    0.253                                          24%        36%    0.177                                          RFS/PFS
  Miyamoto, 2012 \[[@pone.0174746.ref036]\]   ERβ        188            89%                                              49%      \<0.001                                     53%           38%                       0.109   29%    58%    \<0.001                                        34%        67%    \<0.001                                        RFS/PFS
  Nam, 2014 \[[@pone.0174746.ref044]\]        ERβ        169            NA                                               31%      NA                                          31%           31%                       1.000   27%    41%    0.098                                          22% (Ta)   NA     0.004                                          RFS/PFS
                                                                                                                                                                                                                                                                                           42% (T1)          (Ta vs T1)                                     
  Tan, 2015 \[[@pone.0174746.ref048]\]        ERβ        313            NA                                               100%     NA                                          NA            NA                        NA      100%   100%   NS                                             100%       100%   NS                                             NA

AR = androgen receptor, ER = estrogen receptor, NA = not analyzed, M = male, F = female, LG = low-grade, HG = high-grade, NMI = non-muscle-invasive, MI = muscle-invasive, RFS = recurrence-free survival, PFS = progression-free survival, NS = not significant.

\*Original data

Quality assessment {#sec010}
------------------

Quality assessment was performed in each eligible study, using the Newcastle-Ottawa Scale (NOS) (ranging from 0 to 9). This tool has been developed to assess the quality of non-randomized studies to incorporate quality assessments in the interpretation of meta-analysis \[[@pone.0174746.ref035]\]. The NOS scores of 1--3, 4--6, and 7--9 were defined as low-, intermediate-, and high-quality studies, respectively.

Statistical analysis {#sec011}
--------------------

All analyses were carried out using R software (version 3.1.0). ORs and their 95% CIs were calculated based on the numbers from the studies to estimate the association between the expression of sex hormone receptors and pathological features of the tumors. Similarly, the pooled HR for RFS or PFS from published data was calculated by fixed and random-effects models in a multivariate setting. Original data for a study a senior author of the current study previously reported \[[@pone.0174746.ref036]\] were also used for calculating HRs and 95% CIs. Heterogeneity between studies was assessed by the Cochran's Q test and *I*^*2*^ index, as previously described \[[@pone.0174746.ref037]\]. When heterogeneity among the studies was observed, we showed only the estimates of random-effects in the text. Publication bias was evaluated using Begg's test. A *P* value of \<0.05 was considered statistically significant.

Results {#sec012}
=======

Search results and characteristics of included studies {#sec013}
------------------------------------------------------

We identified a total of 114 (AR) and 110 (ER) articles published between 2004 and 2017 by the primary computerized literature search. However, 73 (AR) and 62 (ER) were excluded because they were review articles, articles describing only the results derived from cell lines or animals, articles in non-bladder cancer, or articles written in non-English. The abstracts of the remainder of the articles were reviewed in detail, and 32 (AR) and 40 (ER) were further excluded due to no sufficient data or a different classification from other studies. Finally, 9 and 8 articles regarding AR and ER, respectively, were identified as eligible studies for this meta-analysis ([Fig 1](#pone.0174746.g001){ref-type="fig"}).

![Flowchart of literature search and selection process.\
(a) AR and (b) ER.](pone.0174746.g001){#pone.0174746.g001}

Four of the articles demonstrated the results of multiple receptors, and 13 eligible studies \[[@pone.0174746.ref020], [@pone.0174746.ref036], [@pone.0174746.ref038]--[@pone.0174746.ref048]\] involving a total of 2,049 bladder cancer patients were thus analyzed. The median sample size in these studies was 120 patients (range, 49--472). The relationship between pathological features ([Table 2](#pone.0174746.t002){ref-type="table"}) or prognosis ([Table 3](#pone.0174746.t003){ref-type="table"}) and each receptor expression had been individually assessed in 9 (AR), 2 (ERα), or 7 (ERβ) studies ([Table 1](#pone.0174746.t001){ref-type="table"}).

10.1371/journal.pone.0174746.t002

###### Meta-analysis between sex steroid hormone receptor expression and clinicopathological features of bladder cancers.

![](pone.0174746.t002){#pone.0174746.t002g}

  Stratification                                                                                                                                  Receptor         No. of Study \[reference\]   Patients (N)   Pooled OR (95% CI)   Heterogeneity                       
  ----------------------------------------------------------------------------------------------------------------------------------------------- ---------------- ---------------------------- -------------- -------------------- --------------- --------- --------- ---------
  Non-tumor vs Tumor                                                                                                                              AR               5                            555            1.138                3.256           0.336     95.7      \<0.001
  \[[@pone.0174746.ref036],[@pone.0174746.ref038],[@pone.0174746.ref040],[@pone.0174746.ref042],[@pone.0174746.ref043]\]                          (0.867--1.495)   (0.295--35.998)                                                                                      
  ERα                                                                                                                                             2                308                          0.412          0.605                \<0.001         59.8      0.115     
  \[[@pone.0174746.ref036],[@pone.0174746.ref043]\]                                                                                               (0.265--0.642)   (0.153--2.390)                                                                                       
  ERβ                                                                                                                                             3                438                          0.475          0.580                0.674           95.2      \<0.001   
  \[[@pone.0174746.ref036],[@pone.0174746.ref042],[@pone.0174746.ref047]\]                                                                        (0.327--0.691)   (0.046--7.370)                                                                                       
  Gender (male vs female)                                                                                                                         AR               6                            1075           0.658                0.664           0.027     0         0.653
  \[[@pone.0174746.ref020],[@pone.0174746.ref036],[@pone.0174746.ref038],[@pone.0174746.ref041],[@pone.0174746.ref042],[@pone.0174746.ref044]\]   (0.454--0.954)   (0.457--0.967)                                                                                       
  ERβ                                                                                                                                             3                496                          0.660          0.662                0.101           0         0.559     
  \[[@pone.0174746.ref036],[@pone.0174746.ref042],[@pone.0174746.ref044]\]                                                                        (0.401--1.085)   (0.402--1.088)                                                                                       
  Tumor grade (LG vs HG)                                                                                                                          AR               6                            1075           0.575                0.577           \<0.001   43.9      0.113
  \[[@pone.0174746.ref020],[@pone.0174746.ref036],[@pone.0174746.ref038],[@pone.0174746.ref041],[@pone.0174746.ref043],[@pone.0174746.ref044]\]   (0.421--0.785)   (0.367--0.908)                                                                                       
  ERβ                                                                                                                                             6                1125                         2.169          2.163                \<0.001         0         0.453     
  \[[@pone.0174746.ref036],[@pone.0174746.ref042],[@pone.0174746.ref044],[@pone.0174746.ref045],[@pone.0174746.ref046],[@pone.0174746.ref048]\]   (1.583--2.971)   (1.547--3.023)                                                                                       
  Tumor stage (NMI vs MI)                                                                                                                         AR               5                            912            0.666                0.649           0.356     82.1      \<0.001
  \[[@pone.0174746.ref020],[@pone.0174746.ref036],[@pone.0174746.ref039],[@pone.0174746.ref041],[@pone.0174746.ref042]\]                          (0.476--0.930)   (0.260--1.625)                                                                                       
  ERβ                                                                                                                                             4                864                          3.104          3.077                \<0.001         0         0.389     
  \[[@pone.0174746.ref036],[@pone.0174746.ref042],[@pone.0174746.ref046], [@pone.0174746.ref048]\]                                                (2.081--4.631)   (2.055--4.608)                                                                                       

AR = androgen receptor, ER = estrogen receptor, OR = odds ratio, CI = confidence interval, LG = low-grade, HG = high-grade, NMI = non-muscle-invasive, MI = muscle-invasive.

10.1371/journal.pone.0174746.t003

###### Meta-analysis between sex hormone receptor expression in superficial bladder cancer and patient outcomes.

![](pone.0174746.t003){#pone.0174746.t003g}

  Survival                                                                   Receptor         No. of Study \[reference\]   Patients (N)   Pooled HR (95% CI)   Heterogeneity                   
  -------------------------------------------------------------------------- ---------------- ---------------------------- -------------- -------------------- --------------- ------- ------- -------
  RFS                                                                        AR               3                            496            0.593                0.598           0.006   19.4    0.289
  \[[@pone.0174746.ref036],[@pone.0174746.ref042],[@pone.0174746.ref044]\]   (0.408--0.860)   (0.393--0.911)                                                                                   
  ERβ                                                                        3                496                          1.573          1.573                0.013           0       0.553   
  \[[@pone.0174746.ref036],[@pone.0174746.ref042],[@pone.0174746.ref044]\]   (1.102--2.247)   (1.102--2.247)                                                                                   
  PFS                                                                        AR               2                            327            0.533                0.533           0.223   0       0.425
  \[[@pone.0174746.ref036],[@pone.0174746.ref042]\]                          (0.194--1.465)   (0.194--1.465)                                                                                   
  ERβ                                                                        3                496                          2.236          4.148                0.089           78.2    0.010   
  \[[@pone.0174746.ref036],[@pone.0174746.ref042],[@pone.0174746.ref044]\]   (1.189--4.205)   (0.803--21.411)                                                                                  

RFS = recurrence-free survival, PFS = progression-free survival, AR = androgen receptor, ER = estrogen receptor, HR = hazard ratio, CI = confidence interval.

Quality assessment using the NOS was performed in these 13 studies included in this meta-analysis. The NOSs were 6 or higher ([S2 Fig](#pone.0174746.s002){ref-type="supplementary-material"}), indicating that the quality of the studies was acceptable. In addition, the funnel plots via Begg's test showed no significant bias across publications regarding differences in AR/ERβ expression in normal *vs*. tumor samples, patient genders, tumor grades/stages, or RFS/PFS rates ([S3 Fig](#pone.0174746.s003){ref-type="supplementary-material"}).

AR {#sec014}
--

There were no statistically significant differences in AR expression between non-tumor and tumor (*P* = 0.336), non-tumor and NMI tumor (*P* = 0.664), or non-tumor and MI tumor (*P* = 0.515), as well as between NMI and MI tumors (*P* = 0.356). However, AR expression was significantly down-regulated in female tumors compared with male tumors (OR = 0.658; 95% CI = 0.454--0.954; *P* = 0.027) as well as in high-grade tumors compared with low-grade tumors (OR = 0.575; 95% CI = 0.421--0.785; *P* \< 0.001). In NMI tumors, there was also a significant difference in AR positivity between low-grade and high-grade (OR = 0.457; 95% CI = 0.272--0.768; *P* = 0.003). Significant heterogeneity existed in the meta-analysis of the association of AR expression with non-tumor/tumor (*I*^2^ = 95.7%; *P* \< 0.001) or tumor stage (*I*^2^ = 82.1%; *P* \< 0.001), but not with gender (*P* = 0.653) or tumor grade (*P* = 0.113).

HRs of AR positivity for RFS and PFS were available in 3 and 2 studies accounting for 496 and 327 patients with NMI bladder tumor, respectively. AR expression was significantly associated with better RFS (HR = 0.593; 95% CI = 0.408--0.860; *P* = 0.006), but not PFS (*P* = 0.223). No significant heterogeneity of association between AR expression and RFS (*P* = 0.289) or PFS (*P* = 0.425) was identified. The association between AR expression and prognosis in patients with MI tumor could not be analyzed because only one study \[[@pone.0174746.ref036]\] demonstrated such data.

ERα {#sec015}
---

ERα expression was significantly down-regulated in bladder tumors, compared with non-tumors (OR = 0.412; 95% CI = 0.265--0.642; *P* \< 0.001), with exhibiting no significant heterogeneity (*P* = 0.115). We could not analyze the associations between ERα expression and gender, tumor grade/stage, or prognosis because only one study \[[@pone.0174746.ref036]\] demonstrated such data.

ERβ {#sec016}
---

There was no statistically significant difference in ERβ expression between non-tumor and tumor (*P* = 0.674), non-tumor and NMI tumor (*P* = 0.612), or non-tumor and MI tumor (*P* = 0.663), as well as between male and female tumors (*P* = 0.101). However, ERβ expression was significantly up-regulated in high-grade tumors compared with low-grade tumors (OR = 2.169; 95% CI = 1.583--2.971; *P* \< 0.001) as well as in MI tumors compared with NMI tumors (OR = 3.104; 95% CI = 2.081--4.631; *P* \< 0.001). In a subgroup of NMI tumors, there was no significant difference in ERβ positivity between low-grade and high-grade (*P* = 0.989). Significant heterogeneity existed in the meta-analysis of the association of ERβ expression with non-tumor/tumor (*I*^2^ = 95.2%; *P* \< 0.001), but not with gender (*P* = 0.559) or tumor grade (*P* = 0.453) or stage (*P* = 0.389).

HR of ERβ positivity for either RFS or PFS was available in 3 studies accounting for 496 patients with NMI bladder tumor. ERβ expression was significantly or marginally associated with worse RFS (HR = 1.573; 95% CI = 1.102--2.247; *P* = 0.013) or PFS (HR = 4.148; 95% CI = 0.803--21.411; *P* = 0.089), respectively. No significant heterogeneity of association of ERβ expression with RFS (*P* = 0.553) was seen, whereas that with PFS was significant (*I*^2^ = 78.2%; *P* = 0.010). The association between ERβ expression and prognosis in patients with MI tumor could not be analyzed because only one study \[[@pone.0174746.ref036]\] demonstrated such data.

Discussion {#sec017}
==========

IHC has detected AR protein signals in 13--55% of bladder or upper urinary tract urothelial tumors \[[@pone.0174746.ref019], [@pone.0174746.ref020], [@pone.0174746.ref036], [@pone.0174746.ref038]--[@pone.0174746.ref044], [@pone.0174746.ref049]--[@pone.0174746.ref051]\], which is significantly lower than the positive rates in normal/non-neoplastic urothelial tissues (58--86%) reported by most of respective comparative studies \[[@pone.0174746.ref036], [@pone.0174746.ref038], [@pone.0174746.ref040], [@pone.0174746.ref051]\]. However, at least three immunohistochemical studies have demonstrated no AR expression in normal urothelium \[[@pone.0174746.ref042], [@pone.0174746.ref043], [@pone.0174746.ref052]\]. Significant or insignificant down-regulation of AR expression in high-grade or MI urothelial carcinomas, compared with low-grade or NMI tumors, has also been found \[[@pone.0174746.ref019], [@pone.0174746.ref036], [@pone.0174746.ref038]--[@pone.0174746.ref040], [@pone.0174746.ref042], [@pone.0174746.ref044], [@pone.0174746.ref049]--[@pone.0174746.ref051]\]. However, several studies showed even slight increases in AR positivity in high-grade and/or MI tumors \[[@pone.0174746.ref020], [@pone.0174746.ref041], [@pone.0174746.ref051]\]. Furthermore, two studies each have suggested a considerable association of AR expression in bladder tumors with a higher risk of the progression of only MI disease \[[@pone.0174746.ref036]\] or both NMI and MI diseases \[[@pone.0174746.ref043]\] or a lower risk of the recurrence of NMI disease \[[@pone.0174746.ref042], [@pone.0174746.ref044]\], or no such strong association with the prognosis of patients with NMI or MI disease \[[@pone.0174746.ref040], [@pone.0174746.ref041]\].

Although *ERα* gene expression via a quantitative polymerase chain reaction (PCR) method has been confirmed in all the 10 tumors examined \[[@pone.0174746.ref029]\], ERα signals via IHC in tissue specimens have been detected only in a small subset (*e*.*g*. 1--5%) of bladder cancers in most of previous studies \[[@pone.0174746.ref046], [@pone.0174746.ref048], [@pone.0174746.ref053]\]. In contrast, our IHC showed that ERα was positive in 27% of bladder tumors \[[@pone.0174746.ref036]\] as well as in 18% of upper urinary tract tumors \[[@pone.0174746.ref051]\]. Some of these immunohistochemical studies have also demonstrated elevated levels of ERα expression in non-neoplastic urothelial tissues, compared with bladder tumors \[[@pone.0174746.ref036], [@pone.0174746.ref051], [@pone.0174746.ref053]\], in contrast to the findings in the PCR analysis (*i*.*e*. 2.77-fold stronger expression in tumors than in matched normal tissues) \[[@pone.0174746.ref029]\], as well as in low-grade/NMI tumors, compared with high-grade/MI tumors \[[@pone.0174746.ref036], [@pone.0174746.ref053]\]. In accordance with the IHC data, three separate microarray cohorts of bladder tissues showed significantly lower levels of ERα gene expression in tumor than in normal \[[@pone.0174746.ref054]--[@pone.0174746.ref056]\]. However, none of the studies have shown prognostic significance of ERα expression in patients with urothelial tumor. Our recent study demonstrated that patients with pT3-4 upper urinary tract urothelial carcinoma negative for both ERα and progesterone receptor (PR) had a significantly lower risk of cancer-specific mortality, compared with those showing ERα and/or PR positivity \[[@pone.0174746.ref051]\].

The positive rates of ERβ expression in immunohistochemical studies in urothelial tumor specimens range from 22% to 100% \[[@pone.0174746.ref019], [@pone.0174746.ref036], [@pone.0174746.ref040], [@pone.0174746.ref042], [@pone.0174746.ref044]--[@pone.0174746.ref048], [@pone.0174746.ref051]\], which was significantly lower than those in non-neoplastic urothelial tissues in most of comparative studies \[[@pone.0174746.ref036], [@pone.0174746.ref040], [@pone.0174746.ref047], [@pone.0174746.ref051]\]. In addition, both significant or insignificant up-regulation \[[@pone.0174746.ref036], [@pone.0174746.ref042], [@pone.0174746.ref044]--[@pone.0174746.ref046]\] and down-regulation \[[@pone.0174746.ref047]\] of ERβ expression have been reported in higher grade/stage tumors. Strong associations of ERβ expression with both the risk of recurrence and/or progression of NMI tumors \[[@pone.0174746.ref036], [@pone.0174746.ref042], [@pone.0174746.ref044]\] or progression of MI tumors \[[@pone.0174746.ref036]\] and favorable prognosis in patients with NMI tumor \[[@pone.0174746.ref048]\] have also been documented.

The expression status of sex hormone receptors has thus been assessed in bladder cancer tissues, mainly using IHC, resulting in conflicting results regarding the rate of receptor positivity as well as the relationship between receptor expression and tumor aggressiveness. These included a discrepancy in, for instance, AR positivity between bladder cancer tissues obtained at different institutions but stained at one institution using the same antibody and staining protocol \[[@pone.0174746.ref036], [@pone.0174746.ref041]\]. In addition, the impact of AR/ERα/ERβ expression on patient outcomes as prognosticators remains controversial. As shown in breast tissues \[[@pone.0174746.ref057], [@pone.0174746.ref058]\], these varied data in IHC may be attributed to the differences in antibody specificity or staining strategy as well as tissue preparation including preservation in fixative. We therefore conducted this meta-analysis of previous studies demonstrating the expression of AR, ERα, and ERβ in bladder cancer specimens.

Our analysis for AR expression, showing significant heterogeneity in non-tumor/tumor and tumor stage, but not in tumor grade or prognosis, revealed its strong inverse association with tumor grade, as well as no significant differences between benign bladders versus tumors and between NMI versus MI tumors. Patients with AR-positive NMI tumor were also found to have a significantly lower risk for tumor recurrence, compared to those with AR-negative NMI, but not for disease progression. Interestingly, while each previous study has demonstrated no statistically significant difference in AR positivity between tumors from male versus female patients \[[@pone.0174746.ref020], [@pone.0174746.ref036], [@pone.0174746.ref038], [@pone.0174746.ref041], [@pone.0174746.ref042], [@pone.0174746.ref044]\], the meta-analysis shows significant down-regulation of AR expression in female tumors. The rate of ERα positivity was found to be significantly lower in bladder tumors than in non-tumors. However, no further analysis could be performed due to insufficient number of studies. While ERβ positivity was not significantly different between non-tumors and tumors with significant heterogeneity, as well as between male and female tumors without significant heterogeneity, in the analysis, significant up-regulation was seen in high-grade or MI tumors, compared with low-grade or NMI tumors. Patients with ERβ-positive NMI tumor were also found to have a significantly higher risk for tumor recurrence, compared to those with ERβ-negative NMI tumor. Similarly, there was a tendency to correlate between ERβ expression and disease progression in patients with NMI tumor.

The NOSs of previous non-randomized studies included in this meta-analysis were found to be 6--8, indicating high-quality of each study. In addition, Begg's test revealed no statistical significance, suggesting that this meta-analysis was not biased. Nonetheless, in this study, there are several limitations that need to be carefully considered when interrupting the results. First, as stated above, significant heterogeneity among included studies existed. Second, the potential risk bias was a concern. Because positive results were more likely to be published than negative ones, the meta-analyses based on published data might overestimate clinical significance of the expression status of sex hormone receptors in bladder cancer. Third, there were differences in staining protocol, including antibody, as well as scoring of the stains, used in previous studies, which might have resulted in diverse expression patterns. Finally, all included in this meta-analysis were retrospective studies often susceptible to selection bias.

In summary, we assessed the expression status of AR, ERα, and ERβ in bladder cancers and its potential role as prognosticators. We found some differences in receptor positivity between non-neoplastic bladder tissue and bladder cancer as well as tumor grades or stages. AR or ERβ expression was also found to correlate with tumor recurrence or progression, respectively. These findings support previous preclinical data indicating the involvement of sex hormone receptor signals in urothelial carcinogenesis and cancer progression. Moreover, the rate of AR positivity was significant higher in male tumors than in female tumors, while none of previous studies showed such a statistically significant difference. Because the number of the studies included in the current meta-analysis for each receptor is relatively small, we may need to accumulate more data to re-evaluate the significance of AR/ERα/ERβ expression in bladder cancer outgrowth.
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###### Funnel plots for publication bias test from 3 or more studies in each category.

(TIF)

###### 

Click here for additional data file.

###### The PRISMA checklist of the meta-analysis.
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